Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer's disease: insights from the ADMET 2 trial - PubMed
3 hours ago
- #Alzheimer's disease
- #methylphenidate response
- #lipidomics
- Methylphenidate (MPH) shows modest efficacy for treating apathy in Alzheimer's disease, but treatment responses vary among patients.
- Lipidomic profiling identified lipid species associated with MPH response, with robust discrimination between responders and non-responders (AUC around 0.82-0.84).
- Pathway analysis revealed disruptions in ceramide, phosphosphingolipid, and glycosphingolipid metabolism in MPH responders, with glycosphingolipid metabolism also linked to apathy changes in the placebo group.
- The findings suggest lipid biomarkers may help predict MPH efficacy and provide insights into molecular mechanisms of apathy and treatment response in Alzheimer's disease.